Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 234 points (1.3%) at 18,060 as of Monday, April 20, 2015, 1:15 PM ET. The NYSE advances/declines ratio sits at 2,313 issues advancing vs. 675 declining with 139 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 1.0%. Top gainers within the industry include

Incyte

(

INCY

), up 2.9%,

Alexion Pharmaceuticals

(

ALXN

), up 1.3%,

Amgen

(

AMGN

), up 0.9%,

Regeneron Pharmaceuticals

(

REGN

), up 1.0% and

Bristol-Myers Squibb Company

(

BMY

), up 0.9%. A company within the industry that fell today was

Ampio Pharmaceuticals

(

AMPE

), up 66.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Biogen

(

BIIB

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biogen is up $3.08 (0.7%) to $422.52 on light volume. Thus far, 604,861 shares of Biogen exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $419.00-$424.77 after having opened the day at $424.66 as compared to the previous trading day's close of $419.44.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $100.6 billion and is part of the health care sector. Shares are up 23.6% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Biogen a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Biogen

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Biogen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

AbbVie

(

ABBV

) is up $1.26 (2.0%) to $63.55 on average volume. Thus far, 7.0 million shares of AbbVie exchanged hands as compared to its average daily volume of 12.5 million shares. The stock has ranged in price between $62.80-$64.00 after having opened the day at $62.91 as compared to the previous trading day's close of $62.29.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $99.7 billion and is part of the health care sector. Shares are down 4.8% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AbbVie

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and generally higher debt management risk. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Johnson & Johnson

(

JNJ

) is up $0.90 (0.9%) to $100.48 on light volume. Thus far, 2.9 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.2 million shares. The stock has ranged in price between $100.05-$100.88 after having opened the day at $100.26 as compared to the previous trading day's close of $99.58.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $277.5 billion and is part of the health care sector. Shares are down 4.8% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Johnson & Johnson Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null